DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Pick disease — screening already-approved drugs against its 8-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePick disease maps to a 8-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pick disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
chitinase 3 like 1 (CHI3L1) — CHI3L1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2~{s},5~{s}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8R4X · 1.54 Å · ligand (2~{S},5~{S})-4-[1-(4-chloranylpyridin-2-yl)piperidin-4-yl]-5-[(4-chlorophenyl)methyl]-2-methyl-morpholine (XZ0). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts provided do not describe any drug treatment or repurposing trial for Pick disease. The 2010 and 2012 papers concern Niemann-Pick type C disease, a separate lysosomal storage disorder caused by NPC1 or NPC2 mutations, and discuss lipid storage and calcium homeostasis without testing any drug. The 2011 paper is a retrospective analysis of 21 autopsy-confirmed Pick disease cases from two specialist centres, representing 70% of all Pick disease cases identified at those centres between 1998 and 2007. At presentation, 13 of 21 cases (62%) were clinically diagnosed with behavioural variant frontotemporal dementia and 8 of 21 (38%) with language variant frontotemporal dementia, including two with mixed syndromes. Patients with behavioural variant died on average 5 years earlier than those with language variant (7 years versus 12 years after disease onset). Pathologically, fewer Pick bodies were present in the frontal and inferior temporal cortices of behavioural variant cases than language variant cases, while both groups showed decreased neuronal density in the dentate gyrus with increasing disease duration.
No drug, no intervention, no biomarker change, and no survival benefit from any treatment is reported in any of these abstracts. The 2011 study is purely descriptive of natural history and pathology, and the two Niemann-Pick papers are reviews of basic disease mechanisms. There is no evidence here to support repurposing any compound for Pick disease.
What is still missing is any clinical trial data for Pick disease itself, any drug that has been tested in patients with confirmed Pick pathology, and any validated biomarker or patient stratification method that could be used to design such a trial. Funding for a prospective, pathology-confirmed treatment study in Pick disease has not been reported in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Traffic · 2010 · 207 citations · open access
Lipids on Trial: The Search for the Offending Metabolite in Niemann-Pick type C Disease
AbstractNiemann-Pick disease type C is a complex lysosomal storage disorder caused by mutations in either the NPC1 or NPC2 genes that is characterized at the cellular level by the storage of multiple lipids, defective lysosomal calcium homeostasis and unique trafficking defects. We review the potential role of each of the individual storage lipids in initiating the pathogenic cascade and propose a model of NPC1 and NPC2 function based on the current knowledge.
Clinical phenotypes in autopsy-confirmed Pick disease
AbstractBACKGROUND: Neuropathology of frontotemporal lobar degeneration is variable and relationship between the pathology and the clinical presentation remains uncertain. Abnormal deposits of hyperphosphorylated and ubiquitinated tau protein are present in 30% of cases, which include the classic presentation of Pick disease with argyrophilic, intraneuronal inclusions known as Pick bodies. This study aimed to improve sensitivity of clinicopathologic relations in cases with neuropathologically confirmed Pick disease and to identify clinical symptoms and signs predictive of disease progression. METHODS: This was a retrospective analysis of 21 cases with a pathologic diagnosis of Pick disease and sufficient clinical information to establish early presenting clinical features from 2 specialist centers, representing 70% of all cases of Pick disease identified between 1998 and 2007 in these centers. RESULTS: At presentation, 13/21 cases (62%) were clinically diagnosed with behavioral variant frontotemporal dementia (bvFTD) and 8/21 (38%) with language variant frontotemporal dementia (lvFTD) including 2 with mixed syndromes. Patients with bvFTD died on average 5 years earlier than those with lvFTD (7 years vs 12 years after disease onset). Pathologically, fewer Pick bodies were present in the frontal and inferior temporal cortices of bvFTD than lvFTD cases. In contrast, both groups showed decreased neuronal density in the dentate gyrus with increasing disease duration. CONCLUSIONS: The pathologic course of the disease in FTLD cases with Pick bodies is not uniform and disease duration can be estimated based on early clinical features. These findings have relevance as treatment options, which are likely to be pathology specific, are developed.
Вестник Российской академии медицинских наук · 2012 · 0 citations
КЛИНИКО-ГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ БОЛЕЗНИ НИМАННА–ПИКА, ТИП С
AbstractNiemann-Pick disease, type C is a rare hereditary disorder of the group of lisosomal storage diseases, caused by mutations in the genes NPC1 or NPC2. Depending on the onset age, several clinical forms of this disease, which differs by manifestation age, main clinical signs and clinical course, are distinguished. Niemann-Pick disease type C can imitate other hereditary and acquired diseases, which complicates its early diagnostics. Clinical and genetic diversity of this disorder, considered on the clinical cases diagnosed at the FSI «RCMG» of RAMS, are discussed in this review.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
